Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma company. Redenlab are providing audio capture and analytics for a Phase 1b clinical trial. Conducted in sites across the USA, the study will investigate the long-term efficacy of a treatment designed to ameliorate the impact of this rare and debilitating disease.
Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics for a long-term open label extension clinical trial. Conducted in 8 sites across the USA over 2 years, the study will investigate the long-term efficacy of a treatment designed to ameliorate the debilitating impact of this fatal disease. For the study, Redenlab will provide advanced speech recording and analysis solutions.
Redenlab Inc, the speech neuroscience company delivering insights in speech and language testing, announces that it has been selected by medium sized USA pharmaceutical company to support their upcoming gene therapy study in Friedreich ataxia (FA). Conducted across 5 sites in 3 countries over 2 years, the Phase 2a study will investigate the safety, tolerability and efficacy of gene therapy on adolescents with FA. For the study, Redenlab will provide advanced speech recording and analysis solutions.
Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.